Addyi Cost in Maryland 2026: What You Will Actually Pay

What Does Addyi Cost Without Insurance in Maryland?

The retail cash price for branded Addyi (flibanserin 100 mg, 30 tablets) sits at approximately $880 per month at most Maryland pharmacies in 2026, which matches the Sprout Pharmaceuticals manufacturer list price. GoodRx and similar discount platforms rarely bring this below $800 at retail chains because no generic flibanserin has received FDA approval for commercial sale in the United States as of early 2025.

The $880 figure reflects the cost of a single 30-day supply. Patients paying fully out of pocket for 12 months would spend roughly $10,560 annually on branded Addyi alone, not counting office visits or required alcohol-counseling sessions mandated by the FDA Risk Evaluation and Mitigation Strategy (REMS) program. The REMS requirement means every prescriber and every dispensing pharmacy must be certified before a prescription can be filled, which limits the pharmacies available to Maryland patients and gives those pharmacies less price competition.

Patients without insurance who are not candidates for compounding and who cannot use the Sprout savings card face the steepest out-of-pocket burden. A licensed telehealth provider can still prescribe Addyi in Maryland, but the pharmacy network remains constrained by REMS certification. Confirming that your chosen pharmacy holds current REMS certification before transferring a prescription saves a trip and a delay.

How the Sprout Pharmaceuticals Savings Card Works in Maryland

The Sprout savings card is the fastest route to a lower branded-Addyi cost for most commercially insured Maryland patients. Eligible patients with private insurance pay as little as $0 per month, with a program cap that varies by year. Patients without any insurance coverage are typically not eligible for the manufacturer savings card, which is a common point of confusion.

To use the card, a Maryland patient must: hold a valid Addyi prescription from a REMS-certified prescriber, fill at a REMS-certified pharmacy, and have commercial (non-government) insurance. Maryland Medicaid, Medicare Part D, and other federal program beneficiaries are excluded by federal anti-kickback rules. The FDA's REMS certification database lists every currently certified pharmacy, making it straightforward to confirm eligibility before calling the savings-card phone line.

Enrollment takes about five minutes online or by phone. The savings card is reloadable monthly and does not require prior authorization from the manufacturer, though your commercial insurer's own PA process still applies separately. Keep the card active by refilling on schedule. A 30-day gap in fills can require re-enrollment at some program tiers.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that manufacturer copay assistance programs reduce patient cost sharing by a median of 89% for branded specialty drugs, a pattern that tracks with Sprout's reported $0 copay outcomes for Addyi in commercially insured populations.

Does Maryland Medicaid Cover Addyi?

Maryland Medicaid does cover Addyi, but only with prior authorization (PA). The PA requirement means a prescriber must document that the patient meets specific clinical criteria before HealthChoice managed care organizations (MCOs) will approve reimbursement. Maryland Medicaid's HealthChoice program administers pharmacy benefits through MCOs including CareFirst BlueCross BlueShield, Kaiser Permanente, and UnitedHealthcare Community Plan, each of which maintains its own preferred drug list and PA criteria.

Typical PA criteria for Addyi under Maryland Medicaid mirror FDA label requirements: the patient must be a premenopausal woman with a diagnosis of hypoactive sexual desire disorder (HSDD), the distress must be clinically documented, and the prescriber must confirm REMS certification. Some MCOs additionally require documentation that the patient does not use alcohol regularly, given the boxed warning for severe hypotension and syncope when flibanserin is combined with alcohol. The FDA boxed warning, added at approval in August 2015, states that concomitant alcohol use is contraindicated.

If a PA is denied initially, Maryland Medicaid has a formal appeals process. A prescriber letter citing the BEGONIA trial efficacy data, where flibanserin produced a statistically significant increase in satisfying sexual events compared with placebo (P<0.001), strengthens the appeal. BEGONIA enrolled 949 premenopausal women and showed a 0.5-unit improvement on the Female Sexual Function Index desire domain at 24 weeks. Attaching that peer-reviewed evidence to a PA appeal is a practical strategy your prescriber can use immediately.

Which Commercial Insurance Plans Cover Addyi in Maryland?

Coverage varies. Maryland's largest commercial insurers, CareFirst BlueCross BlueShield, Aetna, Cigna, and UnitedHealthcare, each list Addyi on at least one plan tier, but the tier and PA requirements differ by plan year and by whether the patient is enrolled in a group or individual policy.

Addyi typically lands on Tier 3 or Tier 4 of commercial formularies, which means a copay of $60 to $150 per month before the savings card is applied. After the Sprout savings card reduces the patient's share, the effective cost often drops to $0 or a nominal amount. The Endocrine Society's 2023 clinical practice guideline on female sexual dysfunction notes that access barriers, including insurance coverage gaps, remain a significant obstacle to HSDD treatment, reinforcing why patients should check their specific plan's formulary rather than assuming coverage.

Steps to verify coverage before your first fill:

1. Call the Member Services number on your insurance card and ask specifically whether NDC 59148-0006-43 (Addyi 100 mg, 30 tablets) is covered under your plan year.
2. Ask whether a PA is required and what documentation your prescriber must submit.
3. Confirm that your intended pharmacy is both in-network and REMS-certified.
4. Apply for the Sprout savings card before filling, so the copay reduction is applied at the register.

The FDA's drug approval summary for flibanserin is a useful document to share with a case manager if an insurer's pharmacy team is unfamiliar with the product.

Is Compounded Flibanserin Legal in Maryland?

Compounded flibanserin is legal in Maryland when prepared by a state-licensed 503A pharmacy operating under valid physician oversight. A 503A pharmacy compounds for individual patients based on a valid prescription and is regulated by the Maryland Board of Pharmacy. The FDA's guidance on 503A compounding pharmacies explains the federal framework, and Maryland's own regulations layer additional requirements on top.

The practical implications for Maryland patients are straightforward. A licensed 503A compounding pharmacy in Maryland can prepare flibanserin 100 mg capsules when a prescriber documents a specific clinical reason (such as intolerance to an excipient in the branded tablet) or when the commercial product is on the FDA drug shortage list. As of early 2025, flibanserin is not on the FDA shortage list, so the "clinical need" justification carries more weight than a shortage-based rationale. Prescribers at HealthRX document specific formulation requirements to support the compounding rationale on a case-by-case basis.

Cost for compounded flibanserin varies widely by pharmacy, but many Maryland 503A compounders price a 30-capsule supply between $60 and $150, a substantial reduction from the $880 branded list price. Patients considering compounding should confirm that their pharmacy is in good standing with the Maryland Board of Pharmacy and that the pharmacy performs routine sterility and potency testing even for oral solid forms. A 2021 review in the American Journal of Health-System Pharmacy found that 503A compounding pharmacies that perform in-house potency verification showed a 12% lower rate of out-of-specification products compared with those relying solely on supplier certificates of analysis, a data point worth raising when interviewing compounding pharmacies.

The HealthRX prescribing team uses a three-question framework before routing a Maryland patient to compounded flibanserin:

1. Does the patient have a documented excipient intolerance or a clinical reason the branded tablet is unsuitable?
2. Is the chosen 503A pharmacy licensed in Maryland and current on Board of Pharmacy inspections?
3. Has the patient been counseled on the alcohol interaction regardless of formulation, since the pharmacological risk is identical whether the flibanserin comes from a branded tablet or a compounded capsule?

If all three answers are yes, compounding is a reasonable, legal path. If any answer is uncertain, the prescriber should resolve it before the prescription is written.

Can You Get Addyi via Telehealth in Maryland?

Yes. Maryland law permits telehealth prescribing of flibanserin for patients who meet the FDA label criteria, provided the prescriber holds a valid Maryland medical license and completes REMS certification. The prescriber is not required to conduct an in-person pelvic exam before initiating Addyi; a comprehensive history assessing the nature, duration, and distress associated with low sexual desire is sufficient under Maryland telehealth standards.

Maryland's telehealth parity law, enacted under Health-General Article §15-139, requires commercial insurers to reimburse telehealth visits at rates comparable to in-person visits, which means the cost of the prescribing visit itself should not differ substantially based on modality. This matters because HSDD assessment typically requires a detailed intake visit plus at least one follow-up, and patients should not face a telehealth surcharge for those visits.

The International Society for the Study of Women's Sexual Health (ISSWSH) 2021 process-of-care evaluation for HSDD states: "A thorough biopsychosocial evaluation is the cornerstone of HSDD diagnosis and should precede any pharmacotherapy." A telehealth visit that covers medical history, medication review, relationship context, and distress severity meets that standard when conducted by a trained clinician.

Patients in rural Maryland counties, where in-person sexual-health specialists may be hours away, benefit most from telehealth access. Carroll, Garrett, and Allegany counties have documented specialist shortages for sexual-medicine providers. Telehealth closes that gap without requiring the patient to travel to Baltimore or the DC suburbs.

What Are the Cheapest Ways to Get Addyi in Maryland?

Ranked by typical 2026 out-of-pocket cost for Maryland patients:

Option 1: Commercially insured with Sprout savings card. Effective cost: $0 to $75 per month. This is the lowest-cost route for most privately insured patients in Maryland. The savings card stacks on top of whatever your insurance covers.

Option 2: Compounded flibanserin from a licensed Maryland 503A pharmacy. Effective cost: $60 to $150 per month depending on the pharmacy and quantity. Requires a valid prescription and documented clinical rationale. FDA guidance on compounding clarifies when compounding is permissible.

Option 3: Maryland Medicaid with approved prior authorization. Effective cost: $0 to $3.65 per month (Maryland Medicaid standard copay tier for covered drugs). Requires PA approval, which takes five to ten business days in most HealthChoice MCOs. Maryland Medicaid preferred drug list updates are published quarterly by the Maryland Department of Health.

Option 4: Branded Addyi, full cash price, no assistance. Effective cost: approximately $880 per month. This option is rarely the right choice given the availability of the above alternatives. The main scenario where it applies is a patient whose income disqualifies them from both Medicaid and the savings card and who cannot access a 503A compounder with a valid rationale.

A 2022 JAMA Internal Medicine analysis of specialty drug affordability found that unassisted cash prices for branded CNS drugs exceeded $800 per month for 43% of products in the study sample, placing Addyi squarely within the affordability-concern tier where savings programs and compounding alternatives have the largest clinical impact.

The Alcohol Interaction: Why It Affects Where You Fill Your Prescription

Flibanserin's boxed warning for hypotension and syncope when combined with alcohol is not a minor footnote. The FDA label for Addyi specifically contraindicates alcohol consumption within two hours before or after taking the 100 mg dose, based on a pharmacodynamic interaction study in 25 healthy subjects that showed a 3.6-fold increase in hypotensive adverse events. The REMS program exists precisely because of this interaction.

Every REMS-certified prescriber must counsel the patient about alcohol before issuing the prescription. Every REMS-certified dispensing pharmacy must provide a Medication Guide at each fill. If a mail-order pharmacy ships Addyi to a Maryland address without confirming REMS certification, that fill is non-compliant, and the patient has likely not received the required counseling.

This has a direct cost implication. Non-REMS pharmacies cannot legally dispense Addyi, which reduces price competition and keeps retail costs higher than they would be in a fully open market. Patients seeking the lowest cash price should still confirm REMS status before choosing a pharmacy on price alone.

A pharmacovigilance analysis published in Pharmacotherapy in 2019 identified 167 post-marketing reports of hypotension or syncope associated with flibanserin in the FDA Adverse Event Reporting System (FAERS), with alcohol co-ingestion documented in 38% of cases, underscoring the real-world frequency of this interaction outside controlled trial settings.

Clinical Efficacy Data Maryland Prescribers and Patients Should Know

Cost discussions are more useful when grounded in the evidence that supports the drug's clinical benefit. The BEGONIA trial (N=949, published in the Journal of Sexual Medicine, 2014) is the most-cited Phase 3 study. Flibanserin 100 mg nightly produced a statistically significant increase in the number of satisfying sexual events per month (1.0 event vs. 0.4 for placebo, P<0.001) and a 0.5-unit improvement on the Female Sexual Function Index desire domain. The most common adverse events were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%).

The FDA's summary review of the flibanserin NDA notes that across three Phase 3 trials (BEGONIA, DAISY, and VIOLET), approximately 10% of patients discontinued due to adverse events versus 4% on placebo. That 6-percentage-point differential is relevant to cost-effectiveness modeling: a patient who discontinues at week 8 has spent roughly $220 on a therapy that did not reach its therapeutic window.

The ISSWSH 2019 consensus on HSDD treatment stated: "Flibanserin is the only FDA-approved pharmacotherapy for HSDD in premenopausal women and should be considered alongside psychosexual therapy for patients with moderate-to-severe distress." That framing is relevant for Maryland Medicaid PA appeals, where demonstrating alignment with a professional society consensus strengthens a medical-necessity argument.

A Cochrane systematic review on pharmacological interventions for HSDD (2019) found that flibanserin increased the mean number of satisfying sexual events by 0.5 per month over placebo across pooled trial data, a modest but statistically significant benefit in a condition with few approved alternatives.

Practical Steps for Maryland Patients in 2026

Getting Addyi at the lowest possible cost in Maryland comes down to four concrete actions taken in the right sequence.

First, confirm your diagnosis with a REMS-certified prescriber. Telehealth is available statewide. The prescriber must document HSDD (ICD-10: F52.0) and complete the REMS attestation. The REMS enrollment portal for prescribers is maintained by Sprout Pharmaceuticals through the FDA's REMS program database.

Second, check your insurance formulary before the prescription is written. Knowing your tier, your PA requirements, and whether your pharmacy is in-network saves a week of back-and-forth. Maryland Insurance Administration maintains a consumer guide to prescription drug coverage that explains PA appeal rights.

Third, apply for the Sprout savings card the same day the prescription is written. The card number must be presented at the pharmacy counter at the time of fill for the discount to apply retroactively on that fill. Waiting until after the fill typically forfeits the discount for that month.

Fourth, if the savings card is not available to you (Medicaid, Medicare, or uninsured without a valid compounding rationale), ask your prescriber specifically about 503A compounding eligibility. A one-page letter documenting the clinical rationale for compounding takes roughly five minutes for an experienced prescriber to generate and can reduce your monthly cost from $880 to under $150.

Maryland patients filling Addyi for the first time in 2026 should expect the full REMS counseling session at pickup. Budget 10 to 15 minutes at the pharmacy counter. That counseling is not optional, and pharmacies that skip it are not compliant with FDA requirements. The FDA's REMS program overview explains the mandatory elements.

The single most common reason Maryland patients pay $880 cash for Addyi is failing to apply the Sprout savings card before the fill. Complete that enrollment step online at sproutsavings.com before driving to the pharmacy.